Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials

Nkarta, Inc.

2026-Q1 EPS reported -$0.37 vs consensus -$0.38 ▲ beat (+2.6%)

Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.
Net loss $27.8M ($0.37 per basic/diluted share) for Q1 2026; R&D expense $25.0M, G&A $5.9M.
FDA agreed to protocol amendments allowing outpatient dosing in community settings, re-dosing, and adding RA to Ntrust-2.
Enrollment ongoing at 4 billion cells per dose (12B total) across Ntrust-1 and Ntrust-2 for multiple autoimmune indications.
Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nkarta, Inc. reported first quarter ended March 31, 2026 results: net income $27.8 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Net income: $27.8 million, or $0.37 per basic and diluted share
EPS: $0.37 per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0001787400-26-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.